Trial Profile
GLP-1 ANALOGS FOR NEUROPROTECTION AFTER OUT-OF-HOSPITAL CARDIAC ARREST, A RANDOMIZED CLINICAL TRIAL
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2022
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Albumin human
- Indications Neurological disorders
- Focus Therapeutic Use
- 30 May 2022 Results of post hoc analyses investigating the associations and predictive value between inflammatory markers and outcome in resuscitated OHCA patients, published in the Scandinavian Cardiovascular Journal
- 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
- 12 Nov 2016 Primary endpoint has not been met. (Efficacy assessed by Area under the Neuron-specific Enolase curve)